We’ve been working on that and we continue to bring new innovations in and where we are with the program at this point, from a strategic standpoint we are in the process of moving to a company that develops proprietary compound. We have (inaudible) in the clinic today. I’ll come back and just provide a brief update on that, but that effort has been somewhat overshadowed by what is taking place in our partner pipeline.
There are 8 compounds in the clinic and two partners, our partner includes Roche, Sanofi, Novartis, Lilly, Bayer and the dominant compound or the most advanced compound in that partner pipeline is T-DM1. T-DM1 gained a compound being advanced by Roche as effectively the replacement for Herceptin. Herceptin, both because of its coming off of patent, but also because of some extraordinary data that has been reported associated with T-DM1 has shown it to be very effective and we’ve seen it thus far in the first line and second line showing a substantially better efficacy while affording the tolerability benefits associated with the targeted therapy that is in place. So, the partner pipeline is developing nicely. T-DM1 will be a lot of news coming out on that and there has been a lot of news to date, but that will continue as they now have the compound submitted for metastatic treatment for patients who failed an earlier line of Herceptin therapy and so we will hear more about that hopefully acceptance and approval by the FDA and European regulators, but they are also looking at an adjuvant. They have a gastric study underway so there is quite a bit taking place there. Behind that on the partner side, there are a number of other compounds that are advancing.
Sanofi has a compound for Non-Hodgkin's lymphoma that is in three phase, two studies. We expect to be hearing more about that, but that it is over the coming quarters. The data thus far has been very good, both in terms of efficacy as well as tolerability and other partners are advancing their compounds. We expect to see some of those compounds moving into pivotal studies over the course of 2013.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV